TRANSLATIONAL & COMPARATIVE MEDICAL RESEARCH (TCMR)

TCMR collaborates with external scientific organizations (biotechs, start-ups, universities, government agencies) to de-risk early human health drug discovery packages by applying proof-of-concept studies from the naturally occurring diseases in companion animals that parallel human diseases.

- An extensive full-service R&D unit within Elanco, a division of Eli Lilly and Company
- In-house veterinary scientists, clinical specialists, and operational experts
- Specialize in pre-clinical, drug development with a focus on informing go/no go decisions and creating strong proof-of-concept data packages
- Specialize in the design and implementation of companion animal studies in diseases with parallel human diseases, such as, but not limited to:
  - Oncology
  - Osteoarthritis
  - Gastroenterology
  - Endocrine
  - Pain
  - Autoimmune
  - Heart failure
  - Neurology

High-quality safety and efficacy data from companion animals with naturally occurring diseases that parallel human diseases can increase the marketability of proof-of-concept data packages, particularly for target diseases with high failure rates in Phase II and III clinical trials.

H ave an Idea?

COLLABORATE WITH US.

lilly.com/partners

Neither the content nor any other service presented here is intended to be relied on for medical diagnosis or treatment.